Skip to main content
. 2020 Jul 4;12(7):624. doi: 10.3390/pharmaceutics12070624

Figure 2.

Figure 2

3-ICA decreases lung immune pathology in ABPA. (A) ABPA mouse model. (B) Fungal growth (CFU, mean ± SD), (C) eosinophil recruitment (%), and (D) periodic acid Shiff staining of the lungs of C57BL/6 mice with ABPA and treated with 3-ICA (at 7 days post elicitation) or the vehicle DMSO. (E) Il4 and Il33 specific transcripts in the lungs of ABPA mice treated with 3-ICA. (*** p < 0.001; ** p < 0.001; unpublished data, see Supplementary Materials).